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ABSTRACT
Alshammari, Modhi Abdullah. M.S., Department of Pharmacology and Toxicology,
Wright State University, 2022. Impaired β-cell neogenesis in a mouse model of metabolic
syndrome.
Pancreatic islet β-cell plays an essential role in insulin release and hence glucose
homeostasis. The maintenance of glucose homeostasis depends on β-cell ability to cope
with enough insulin to fulfill metabolic and physiological demands. Adequate insulin
release is the result of highly complex and dynamic interplays between acute changes in βcell electrical activity, exocytosis and chronic adaptations in cellular function, volume,
mass and proliferation. All of this appears modulated, to some extent, by the functional
presence of Slc12a2 symporters, also known as Na+K+2Cl– cotransporter-1 (Nkcc1), which
accumulates intracellular Cl– above its electrochemical equilibrium. Recent studies from
our laboratory showed that mice lacking Nkcc1 in β-cell (Nkcc1βKO) develop a cluster of
metabolic phenotypes reminiscent of the metabolic syndrome i.e., hyperglycemia,
hyperinsulinemia, glucose intolerance, insulin resistance, steatohepatitis and overweight.
The present study is aimed at determining the potential relationship between those
phenotypes and pancreas morphometric parameters including islet size, β-cell number,
volume, mass and neogenesis. The results presented here indicate that elimination of Nkcc1
from β-cell negatively impact those parameters, even before the onset of overweight and
its metabolic complications. Therefore, we propose that Nkcc1 plays a potential causative
role in the development of metabolic syndrome.
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INTRODUCTION
Obesity, metabolic syndrome and type-2 diabetes
The prevalence of obesity, metabolic syndrome and type 2-diabetes (T2D) are
significantly increasing worldwide in an interlinked manner, possibly associated to
common environmental, genetics and behavioral factors including poor dietary habits,
physical inactivity, and genetic predisposition [1]. Yet, the cause/s of obesity, metabolic
syndrome, and T2D remain to be determined.
Insulin, being the main hormone responsible to lower blood glucose and maintain
its homeostasis, is considered a major player in the development of obesity, metabolic
syndrome and T2D. The current concept is that insulin should be released in an equilibrated
manner to maintain glucose homeostasis and lessen the development of the metabolic
disorders. This is achieved, for the most part, by the action of insulin-secreting -cells of
the islets of Langerhans in the pancreas. In our research, we are aiming to investigate the
relationship between metabolic complications of an animal model of metabolic syndrome
and pancreas morphometric parameters, including islet size, -cell number, volume, mass
and neogenesis to better predict the onset of the metabolic complications. In the following
sections, I will provide a brief overview of main metabolic disorders and their interrelationship, mechanisms of insulin release, pancreas anatomy and common -cell adaptive
mechanisms to cope with metabolic demands.
Obesity
An international network of scientists, NCD Risk Factor Collaboration
(ncdrisc.org), estimates that approximately 40% and 12% of the adult world population are

overweight or obese, respectively. These percentages reflect a triplication in the prevalence
of obese individuals since data began to be recorded in 1975. If this trend continues, it is
predicted that nearly 20% of the world population may become obese by 2025 [2]. The
causes of this rapid increase in obesity prevalence are multiple and difficult to individualize
or unravel. Nevertheless, it appears that the propensity to become obese follows many
interacting environmental and biological/genetic factors, which ultimately underlie the
natural variation in body weight responses to a widely available and constantly encouraged
"obesogenic" environment [3].
Obesity has been classically divided into two major categories: i) monogenic, and
ii) polygenic obesity, as summarized in Figure 1. The monogenic forms of obesity are
exceptionally rare and typically consequence of single point mutations in genes involved
in the control of energy intake and metabolism [3]. However, polygenic obesity, like any
other disease with complex genetic traits, is considered the result of many genetic
polymorphisms, which individually may exert small effects on body weight, but together
may increase its prevalence or risk. For instance, single nucleotide polymorphisms (SNPs)
in the fat mass and obesity associated (FTO) gene are considered common genetic basis of
obesity [4, 5]. In fact, children harboring SNPs in the FTO gene are lean, but show reduced
satiation/satiety responses to food [4, 5] and become obese [6-11] and centrally resistant to
insulin later in life [12, 13]. In addition to SNPs in FTO and other recently identified genes
[14], SNPs in the human SLC12A2 gene i.e., Nkcc1 have been recently associated to higher
adiposity in humans [15-17]. Notably, the FTO gene and Nkcc1 are expressed in -cells
and are involved in the regulation of insulin secretion [18-20]. Hence, a physiological link
between -cell Nkcc1, feeding, fat mass and metabolic health may exist in humans.

A

B

Polygenic
Combination of genetic
polymorphisms

Monogenic
Single mutations in genes
responsible for energy
intake and metabolism

Leptin
SNPs in the fat mass
and obesity associated
gene (FTO) or the
melanocortin-4 receptor
gene (MC4R)

Leptin receptors
Melanocortin 4 receptors
Proopiomelanocortin

Figure 1. Obesity types and classification. A. Polygenic types of obesity are believed to be
caused by a combination or sum of single nucleotide polymorphisms (SNPs) in genes involved in
energy homeostasis such as the FTO or MC4R genes and othres. Although these variants are
expected to be found in obese individuals, they are also found in lean people. Therefore, the
relationshoip between these variants and obesity must be statistically validated by demonstrating
that a particular SNP or a group of them exist more frequently in obese individuals than in lean ones.
B. Monogenic types of obesity are mainly due to point mutations in genes directly involved in the
regulation of energy handling and metabolism. They are usually of autosomal recessive inheritance.
Several mutant genes have been linked to monogenic obesity: LEP (leptin), LEPR (leptin receptor),
LEP (leptin), POMC (proopiomelanocortin), M4CR (melanocortin-4 receptor) and others.
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Nonetheless, both forms of obesity do overlap in the sense that the underlying
biology and physiology of body weight regulation appear ultimately controlled by the
central nervous system [21]. Currently, it is believed that the cause of obesity is
unquestionably due to an imbalance between energy intake and energy expenditure [22,
23]. This thermodynamic view of the energy balance model stands behind the widely
accepted hypothesis that obesity results from excessive fat mass accumulation due to
overconsumption of foods rich in fats and reduced energy expenditure due to a sedentary
lifestyle [24, 25].
However, it is apparently clear that inactivity does not cause obesity and that body
weight gain can happen in the absence of increased energy intake. In fact, the energy
balance model of obesity may require further unbiased biological testing because obesity
rates have not decreased in the last 40 years in spite of persistent emphasis in eating less
and exercising more [26, 27]. Most notably, the overall consumption of dietary fats has
substantially decreased by ~8% in the last decades [28]. Therefore, the assumed causal
relationship between overconsumption of fatty foods and obesity remains contentious.
A major caveat of the thermodynamic energy balance model of obesity is that it
does not consider the biological aspects involved in energy partition or efficiency.
Therefore, this model does not account for the fact that body weight and in particular fat
mass accrual are under the control of multiple organs and hormones secreted in response
to, during, or after feeding. These organs and hormones are all responsible for the
regulation of several metabolic pathways directly or indirectly involved in energy
conversion, distribution and redistribution. Therefore, it seems that attributing obesity to a
single hormone or, more commonly, to a simple change in the energy balance equation is

likely to represent a limited view of the pathophysiology of obesity.
Nevertheless, as mentioned earlier, obesity in humans and mouse models can be
caused by deficient secretion and/or action of leptin, an anorexigenic hormone released
from adipocytes and present in plasma in proportion to fat mass [29, 30]. Similarly,
exceptionally rare human genetic conditions not directly related to leptin, but to common
hypothalamic pathways involved in eating behavior can lead to overweight/obesity in
humans as well. For example, monogenic obesity has been described due to mutations in
genes of the melanocortin pathway such as the melanocortin 4 receptor, the
neuropeptide/hormone pro-opiomelanocortin and several others [3]. Accordingly, several
animal models of monogenic obesity including the leptin- and leptin receptor-deficient
mice (ob/ob and db/db mice, respectively) or the Zucker/ZDF (fa/fa) and Koletsky rat
models of morbid obesity [31] have been studied and thoroughly characterized over the
years. These models have indeed provided vital information and knowledge on the
pathophysiology of obesity complications such as hyperglycemia, insulin resistance or
metabolic syndrome. Further, these animal models have played pivotal roles in the
identification of many neuronal pathways involved in the control of feeding behavior,
energy intake or body weight gain and encouraged the generation of new animal models of
obesity harboring specific mutations in genes directly or indirectly involved in the central
control of food intake [31]. Nevertheless, these models of extreme genetic obesity may not
fully represent the complex spectrum of obesity development in humans.
Indeed, contrasting to the wealth of knowledge built from rodent models of
monogenic obesity, far less is known regarding mechanisms of obesity within the context
of the disease as a polygenic syndrome. This is in part due to the limited availability of

animal models spontaneously recapitulating the natural history of overweight. In this
regard, the Fatzo/Pco mouse model, which spontaneously develop age-dependent obesity
and the metabolic syndrome under standard dieting [32] has not been extensively studied
within that context, but rather as an animal model of non-alcoholic fat liver disease
(NAFLD) and/or steatohepatitis (NASH) [33-37]. Instead, the scientific community has
relied much more on rodent models of diet induced obesity (DIO) due to the generalized
view that forcing animal models to eat diets exceptionally rich in fats, usually labeled as
"cafeteria diets" or "Western diets", better represent polygenic obesity in humans [31, 38].
Although the contribution high-fat diets to the development of obesity in humans is
contentious [39], it is clear that obesity and its complications including metabolic syndrome
and, in some instances T2D can be forced to develop in animal models subjected to high
fat diets [38]. Much less clear, however, is the role that non-fatty/high carbohydrate diets
may have on the development of overweight/obesity, in particular within the context that
obesity prevalence has increased in the last decades in spite of the fact that the consumption
of fatty diets has indeed concomitantly decreased [28].
The metabolic syndrome
Closely associated to obesity is the metabolic syndrome. This syndrome is defined
as a constellation of clinical conditions including overweight/obesity, impaired glucose
metabolism, hyperinsulinemia, hyperlipidemia and hypertension [40-42]. These conditions
increase the overall risk for cardiovascular disease (CVD) and T2D, as represented in
Figure 2 [43-47]. In fact, T2D exacerbates the risk for CVD in patients with metabolic
syndrome and the latter, when present with obesity, is considered the primary cause of
NAFLD [48-50].

OH
O

HO
HO

OH
OH
Impaired glucose metabolism

Hypertension

Metabolic Syndrome

Overweight/Obesity

NH

2

Hyperlipidemia

S
S S

S
S

S

Hyperinsulinemia

Type-2 diabetes

Cardiovascular disease

Figure 2. The associated risk factors defining metabolic syndrome. Metabolic syndrome is
characterized by a constellation of risk factors. These are: impaired glucose tolerance, overweight
and/or obesity, insulin resistance and hyperinsulinemia, hypertriglyceridemia, hypercholesterolemia, hyperglycerolemia (hyperlipidemia) and hypertension. The presence of at least three of these
risk factors defines the presence of metabolic syndrome. Combined, these risk factors increased
the absolute risk of development type-2 diabetes (T2D) and cardiovascular disease (CVD).
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The current view is that a positive energy balance is what drives metabolic
syndrome based on the premise that obesity is the main contributing factor for the
development the syndrome [51]. However, it is possible to find key components of the
metabolic syndrome, including NAFLD in lean individuals [52-54]. In fact, ad libitum
chow-fed mouse models of metabolic syndrome i.e., Fatzo/Pco mice spontaneously
develop age-dependent hyperglycemia, hyperinsulinemia, hypertriglyceridemia and
glucose intolerance when they are obese [32] and mice lacking Nkcc1 in -cells develop a
metabolic phenotype resembling metabolic syndrome without increasing their energy
intake [Manuscript under review].
Similarly, there is a partial mutual inter-relationship between obesity and decreased
tissue responses to insulin i.e., insulin resistance (see next Section), a highly complex
clinical condition characterized by chronic hyperinsulinemia and normo/hyperglycemia.
Indeed, the metabolic syndrome is characteristically accompanied by persistent
hyperinsulinemia due to a combination of factors related to hypersecretion of insulin from
pancreatic islet -cells in response to diets rich in carbohydrates, reduced tissue clearance
of the hormone and -cell dysfunction, which ultimately determines the onset of T2D [5557]. Therefore, obesity has long been considered the main cause of insulin resistance, in
turn regarded as the hallmark of metabolic syndrome and a key player in the development
of hyperinsulinemia and even the etiology of T2D [58, 59]. However, this long-held notion
might need revision [23] since hyperinsulinemia can precede insulin resistance as well as
fat mass accrual in animal models [60] and in humans. Indeed, it has long been known that
Pima Indians, who have abnormally high rates of obesity and T2D [61] are
hyperinsulinemic likely due to exaggerated insulin responses to nutrients [62] whereas their

children become hyperinsulinemic before becoming obese [63, 64]. It appears that the
relationship between early hyperinsulinemia and the development of obesity later in life
found in Pima Indians also exists in other ethnic groups [65-68].
Insulin resistance
Although the etiology of metabolic syndrome is intricately complex, it is common
to find in the literature that many authors attribute its pathophysiology to obesity and
insulin resistance, or whatever may occur first [43, 69, 70]. At any rate, the notion that
insulin resistance drives obesity or that the latter causes the former remains a hotly debated
issue [71, 72]. Similarly, the hypothesis that insulin resistance is a physiological response
to over-consumption of diets rich in carbohydrates rather than a pathological response to
obesity has also remained a popular subject of debate [73-75]. Irrespective of its causes or
its classic definition as: "...the inability of a known quantity of exogenous or endogenous
insulin to increase glucose uptake and utilization in an individual as much as it does in a
normal population." [76], insulin resistance has been considered a fundamental etiological
component of T2D. Notably, current guidelines from the Center for Disease Control and
Prevention

(CDC,

www.cdc.gov/diabetes/basics/insulin-resistance.html)

and

the

American Diabetes Association (ADA, www.diabetes.org/healthy-living/medicationtreatments/insulin-resistance) emphasize the importance of detecting insulin resistance to
help prevent the development of T2D.
Type-2 diabetes
It is generally accepted that the failure of insulin-secreting -cells to compensate
for the increased demand of fuels during obesity and states of chronic insulin resistance is
what ultimately drives the development of T2D [70, 77, 78]. Therefore, obesity, the

metabolic syndrome and insulin resistance all appear to increase the absolute risk of
developing T2D. In fact, it is the combination of these risk factors and a number of
additional ones what ultimately may increase the overall risk of T2D, because not all obese
individuals develop diabetes [79]. These risk factors are usually divided into two main
categories: i) non-modifiable risk factors, and ii) modifiable risk factors [78]. The former
ones include ethnicity, sex, age and genetic predisposition [78, 80, 81], whereas the latter
ones relate to environmental factors with the potential to directly or indirectly modify body
weight gain or net body weight (overweight/obesity), diet, physical activity and many
others [78, 80].
It is apparently clear that T2D represents a chronic metabolic disorder characterized
by persistent hyperglycemia consequence of defective insulin secretion in turn aggravated
by the usual peripheral insulin resistance that co-exists in many overweight/obese
individuals. Particularly, hyperglycemia develops gradually in T2D patients and they may
remain asymptomatic for a long time before they are diagnosed [81]. Current guidelines
indicate that the diagnosis of T2D is confirmed when the patient has a persistent fasting
hyperglycemia ( 126 mg/dL) and increased glycated hemoglobin A1c (HbA1c, 6.5%)
[82, 83] in turn accompanied by different symptoms including fatigue, excessive thirst,
frequent urination and others [81]. Uncontrolled T2D results in serious long-term chronic
complications, which are exacerbated by chronic dyslipidemia and additional risk factors
associated with it, including atherosclerosis, stroke and heart attack [84]. Additional
chronic complications of T2D include retinopathy and nephropathy, which can lead to
vision loss and renal failure, respectively [84].
Although the pathogenesis of T2D is yet to be fully understood, many studies have

related the onset of T2D with a decreased function and/or number of islets -cells [78, 81].
Current knowledge supports the hypothesis that T2D endures when dysfunctional -cells
cannot effectively regulate glucose metabolism under high demand [78, 85]. In addition, it
has been recently proposed that fast-decreasing -cell mass can trigger T2D [86], a view
not shared by some scientists based on the common circular egg-chicken dilemma of
causality, an argument that cannot explain what comes first, either -cell dysfunction or
reduced -cell mass [87, 88]. Although it is possible that both conditions may co-develop
or be inter-related, a wealth of research conducted during the last 50 years has been focused
on the functional mechanisms of insulin secretion,

-cell generation/re-generation,

proliferation and replication as the main targets to improve the chances to reduce the
incidence of T2D.
Insulin, being the only glucose-lowering hormone [89], plays a major role in the
maintenance of glucose homeostasis and general metabolic health, growth and feeding
behavior [90, 91]. Therefore, primary disturbances in insulin secretion or secondary in
response to feeding may lead to disrupted fuel homeostasis, which in the long-term may
result in the development of previously mentioned chronic metabolic disorders: obesity,
metabolic syndrome and T2D [89, 92]. Therefore, in the following section the nature and
the mechanisms of insulin release are briefly discussed.
Mechanisms of insulin secretion
Insulin secreting -cells dynamically respond to the changing availability of many
different hormonal, neurotransmitter and fuel inputs; being glucose, considered the most
important of them all [93], but clearly not the only one. Indeed, glucagon, somatostatin,
growth and thyroid hormones, -aminobutyric acid (GABA), nor-epinephrine, epinephrine,

dopamine, incretins such as glucagon-like peptide-1 (GLP-1) and glucose induced-peptide
(GIP), as well as circulating nutrients in the form of amino acids or lipids, all participate in
the integrated regulation of insulin release [93].
Insulin secretion occurs in a biphasic manner. The first phase, which lasts
approximately 4-5 minutes depends on the circulating glucose concentrations and the rise
of Ca2+ levels in -cells [94]. The second phase, is a potentiation of the first one but
independent of Ca2+ signaling and lasts longer until euglycemia is reached [95, 96]. Both,
the first and second phases of insulin secretion are disturbed, to different extents, in T2D
patients [97], but a loss or a disturbance in the first phase is usually considered an early
sign of T2D [98, 99].
Insulin pulsatility and its relationship with obesity and metabolic syndrome
Insulin secretion is pulsatile and reflected as oscillations in its plasma concentration
[100]. When -cells are stimulated with glucose, insulin is secreted in bursts or pulses [100]
characterized by fast, short term increases with a period of ~8-15 minutes and slow, long
term “ultradian” periods of ~80-180 minutes [101, 102]. Together with the oscillatory
nature of insulin secretion, the intracellular Ca2+ concentration ([Ca2+]i) in -cell also
oscillates. It is well known that increased [Ca2+]i is the most important driver of insulin
exocytosis [103-106] and that its influx occurs simultaneously with the closing of ATPdependent K+ (KATP)-channels [107] and the increase in -cell electrical activity [108, 109].
Therefore, it is believed that [Ca2+]i oscillations are the main underlying effectors of the
pulsatile insulin release [99, 100, 110-112].
There is a growing interest in the relationship between insulin oscillation rhythms
and insulin sensitivity in obesity and T2D [100-102, 113]. Impaired insulin oscillation is

generally associated with decreased insulin sensitivity [101, 114]. Although the
mechanisms are not known, it is commonly hypothesized that insulin pulsatility allows
hepatic insulin receptors to be intermittently exposed to insulin thus preventing its downregulation thus enhancing insulin sensitivity [101] and promoting the hepatic clearance of
insulin [115]. This hypothesis has been supported by several studies demonstrating that
intermittent insulin delivery into the portal vein has greater effect on lowering glucose
levels than continuous infusions [116, 117]. In addition, the interval of time between
insulin pulses seems to play an important role in insulin sensitivity since its lengthening
during short-term insulin oscillations i.e., decreasing pulse frequency was associated with
increased insulin sensitivity [101].
Interestingly, the inter-pulse interval of insulin oscillations shortens with increasing
waist-to-hip ratio (WHR) or body weight of obese patients [101, 114] uncovering an
association between abnormal insulin pulsatility and obesity. Further, increased WHR also
associates with decreased peripheral insulin sensitivity while increased adiposity generally
associates with insulin hypersecretion in response to food [118-120], being both important
driving factors for the development of insulin resistance [91]. Increased insulin resistance
could be an early sign of developing T2D since they have been observed in T2D first degree
relatives as well [101, 102, 113]. These relationships between abnormal insulin pulsatility
and obesity/T2D appear to exist in animal models of obesity as well. For instance, the
hyperglycemia, hyperinsulinemia and insulin resistance of ob/ob mice have been
associated with irregularities in insulin oscillations [100, 120]. However, irrespective of
the associations, whether abnormal insulin oscillation causes obesity or the later triggers
the former remains to be formally demonstrated.

Consensus and inclusive mechanisms of insulin release
Of the many ionic mechanisms underlying insulin release, one is well studied: the
one involving KATP-channels, schematized in Figure 3 [20]. This consensus model of
insulin secretion usually follows an oversimplified sequence of events, which is reproduced
in most medical/endocrinology textbooks. These can be summarized as follows. When
glucose levels increase i.e., 6–25mM, the closure of KATP-channels depolarizes the plasma
membrane of -cells provoking the opening of Ca2+ channels and a massive accumulation
of intracellular Ca2+, which ultimately triggers exocytosis of insulin granules [103-105].
More refined versions of this consensus model do exist and include additional players in
the main sequence of events. For instance, under unstimulated conditions i.e., <6mM
glucose, -cell membrane potential remains hyperpolarized at –70mV and insulin secretion
is minimal but existent i.e., basal secretion. When glucose increases during a meal, for
instance, glucose enters -cells through a facilitative transporter e.g., Slc4a2 (Glut2) [105].
Intracellular glucose is immediately phosphorylated by the action of a glucokinase enzyme
to form glucose-6-phosphate, the main substrate of glycolysis [105]. The further
metabolism of glucose produces oxidation substrates for the Krebs cycle resulting in
overproduction of adenosine triphosphate (ATP) relative to adenosine monophosphate
(AMP ) leading to an increase in the ATP/ADP ratio [121]. It is the increase in the total
ATP/ADP ratio what is considered the main stimulus that closes KATP-channels reducing
K+ fluxes thereby depolarizing

-cell plasma membrane to a voltage threshold of

approximately –50mV [104], at which voltage-gated Ca2+ channels open, thereby allowing
the entry of Ca2+ into -cells provoking action potentials and exocytosis of insulin granules
[20, 105].
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Pyruvate
Glucose-6-P

Closure
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Figure 3. The consensus mechanism of insulin release.
through a facilitated transport mechanism mediated by the glucose transporter-2 (GLUT-2). Once
glucose reaches the cytoplasm, it is phosphorylated by a hexokinase to generate glucose-6-phosphate (glucose-6-P), a substrate for the glycolytic pathway to generate pyruvate. The increase in
this substrate promotes its oxidative degradation through the Krebs cycle to produce energy in the
form of adenosine-triphosphate (ATP) thus increasing the molar ratio between ATP and adenosine-diphosphate (ADP). It is believed that such increase in the ATP/ADP ratio is sufficient to close
ATP-dependent K+ channels (KATP-channels) reducing K+ conductance and leading to plasma
membrane depolarization. The consequent opening of voltage-dependent Ca2+ channels (VDCC)
allows the massive entry of Ca2+ ions into
sis of insulin-containing granules. Picture redrawn from [100].
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Simple as it sounds, most notably the consensus mechanism of insulin secretion
does not consider many other KATP-channel-independent anionic mechanisms known to
regulate the electrical activity of -cells in response to nutrients [103]. Indeed, many studies
have demonstrated that insulin secretion in response to glucose and electrical activity still
happen in the molecular or functional absence of KATP-channels, at least in mice [95, 122125]. In humans, however, mutations in the sulfonylurea receptor-1 (SUR1), a fundamental
component of KATP-channels, result in exaggerated or deficient insulin responses to
nutrients [126], rather than absent. Therefore, additional ionic mechanisms participate in
the secretion of insulin in response to glucose. The most studied of them are related to Cl–
channels and transporters [20]. Since -cells regulate and keep their intracellular Cl–
concentration ([Cl–]i) above its thermodynamic equilibrium [105, 127, 128], electrogenic
Cl– fluxes through Cl– channels regulate -cell electrical activity [105]. For [Cl–]i to be
above equilibrium in -cells, there must be Cl– transporters in these cells in charge of
keeping it a non-equilibrium distribution [20]. This is indeed the case, -cells express many
Cl– transporters and channels, each of them individually involved, to different extents, in
the regulation of the electrical activity of these cells. For instance, volume-regulated anion
channels (VRAC) [124], the Ca2+-activated Cl– channel anoctamine-1 (Ano1) [129], the
cystic fibrosis transmembrane conductance regulator (Cftr) [130] and several other Cl–
channels [131, 132] all participate in glucose induced plasma membrane depolarization and
insulin secretion, as schematized in Figure 4. In fact, inhibition of all Cl– channels using
non-specific drugs stabilizes plasma membrane potential, impairs the overall insulin
secretory response to glucose [127] and abolishes Ca2+ oscillations [133].
Similarly, blocking transporters involved in the loading of Cl– into -cells such as

Cl

Glucose
GLUT-2

NKCCs
Cl

Cl
Cl

Krebs
Cycle

30

V
70

swelling?

+

K+

K

KCCs

Cl
Cl

Cl– channels

+2

Ca

Ca +2

VDCC
Ca

+2

Ca

Cl
Cl
Cl

+2

Figure 4. Anionic mechanisms of insulin secretion. In the left hand sice of the model, the
consensus model of insulin secretion is shown (see Figure 3). In the right side of the model,
represented are anionic (Cl–) mechanisms known to participate in the overall secretory response.
Glycolysis and the oxidative phosphorylation of glycolytic substrates are believed to produce
osmotically active metabolites that promote water entry and
Cl– channels, which allows the electrogenic exit of Cl– ions (and
+
in addition to the closure of K
+
–
depolarization (reduced K
Cl
membrane depolarization (increased Cl– efflux) both contributing to the opening of
2+ channels (VDCC) thus allowing the entry of Ca2+ into
release. Figure adapted from [117].
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Nkcc1 and others reduce [Cl–]i, Ca2+ influxes and electrical activity [105, 134] thus
inhibiting insulin secretion [105, 134]. Along these lines, pharmacological inhibition of the
Cl– extruder Kcc2 (Slc12a5) increases insulin secretion [135]. Therefore, Cl– transporters
and channels do participate in the insulin secretory response of -cells.
Role of Cl– transporters and channels in cell proliferation and cell volume regulation
Although the roles of Cl– transporters and channels in insulin secretion are usually
considered of marginal relevance relative to that of the consensus mechanism [103, 134],
it has become apparent that Cl– transporters and channels regulate cell proliferation and
volume in a number of different cell types [136-138]. For instance, activation of GABAAreceptors, which are Cl– channels, increases mouse and human -cell mass [139, 140].
Further, in the particular case of Nkcc1, its involvement in cell proliferation has been long
known to promote the replication of a carcinoma cells including esophageal squamous cells
[141], glial cells [142], as well as prostatic cells [143-150]. In addition, cell proliferation
and cell volume are intimately related physiological processes [151] and Nkcc1 regulates
and maintains cellular volume in all cells studied so far [152], including -cells [153].
Along these lines, inhibition of Nkcc1 [154-156] or its elimination [157] results in shrunken
-cells. Notably, shrunken

-cells have been detected in some T2D patients [158].

Therefore, in addition to the known short-term regulation of insulin secretion, Cl–
transporters and channels may play potential roles in -cell proliferation and/or volume
regulation, which in turn could influence the secretory response in the long term.
Therefore, adaptive -cell mechanisms involving cell volume, proliferation or
growth may predict the development of metabolic disturbances. These potential changes
in -cell volume or number can be morphometrically studied in pancreatic sections.

Consequently, the following sections deal with pancreas anatomy and islet morphology to
better understand morphometry analysis.
Pancreas anatomy
The human pancreas is a retroperitoneal gland that weighs ~100g. It is located at
the left upper abdomen area, behind the stomach [159]. Anatomically, as shown in Figure
5, the human pancreas is a well-defined organ that can be divided into four parts i.e., head,
neck, body and tail, being the head close to the duodenum and the tail adjacent to the spleen
[159]. The mouse pancreas, which weighs ten times less than the human one is not a welldefined organ. Rather, it is found dispersed within the small intestine and is usually divided
into three, rather than four lobes i.e., duodenal, splenic and gastric [160].
The pancreas has a predominant physiological role in regulating fuel homeostasis
and metabolism; and accordingly, it is anatomically divided into two components, one
exocrine and another endocrine [161]. The exocrine portion is composed of ducts and
acinar cells or “acinus”, which are represented in Figure 5 [159]. Ductal cells are
responsible for fluid secretion aimed at maintaining the basic pH of the intestine [159].
Acinar cells, which are grouped in lobules called acini [162], comprise about 85% of the
pancreas mass and they are responsible for secreting multiple digestive enzymes such as
lipases, proteinases and amylases which are secreted into the duodenum [159, 162] to help
digest lipids, proteins and carbohydrates of the diet [161].
The endocrine portion of the pancreas makes up ~1-2% of the whole organ mass
[163, 164]. It consists of randomly distributed clusters of electrically excitable endocrine
cells arranged in irregular small groups, usually round or oval, known as the islets of
Langerhans “insulae pancreaticae” [164]. Islets also contain several types of non-
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Islet of Langerhans

Figure 5. Pancreas anatomy in mice and humans. Represented are pancreas organs from a
mouse (left) and human (right). In the first case, the pancreas organ is diffusely found behind the
stomach, spleen and in close proximity to the duodenum. Accordingly, the mouse pancreas is
anatomically divided in three lobes: duodenal, gastric and splenic pancreas. The human pancreas,
however, has a well-defined form and it accordingly considered to have a head, neck, body and tail.
Each section on the pancreas contain different numbers of small clusters containing different endocrine cells: the islets of Langerhans, which are surrounded by acinar tissue. The latter conform most
of the pancreas parenchyma.
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endocrine cells such as endothelial vascular cells, immune cells, mesenchymal and
neuronal cells [165], all arranged in a way believed to facilitate contact and communication
of all islet cells in order to work in functional harmony [166, 167].
Pancreatic islets are often found dispersed in between acinar regions, as shown in
Figure 5D, and are highly vascularized and innervated [162, 164, 168]. The islet number
increases exponentially with the size of the species [165]. For example, a human or a mouse
pancreas contains ~15 million or 5 thousand islets, respectively [160]. Contrary to their
number, the size of an islet does not depend on the size of the species from where they
come. In fact, islet size and its size distribution exhibiting a diameter range between 30µm
to >400 m are highly similar in all mammals studied so far [169]. According to some
authors, the inter-species similarities in islet size is due to a functional limit, meaning that
an islet may not exceed a certain size in order to be properly functional [170]. Nevertheless,
even within a species, the size of islets may increase depending on physiological and/or
pathological conditions, such as pregnancy, overweight or obesity i.e., where the demand
for fuel handling is increased [170].
Endocrine cells of the islet, distribution and function
The pancreatic islet is composed by different endocrine cells with the capacity to
secrete distinctive hormones including insulin and glucagon directly into the circulation in
response to a variety of nutrients, most notably glucose to maintain blood levels within
physiological ranges. Approximately 50–80% of endocrine islet cells are -cells, which
secrete insulin whereas glucagon-secreting -cells comprise ~10–20% of all islet endocrine
cells. Somatostatin and other bioactive peptides such as pancreatic polypeptide or the
hunger hormone ghrelin are secreted by -, -, and -cells, respectively [93, 171], which

together conform less than 5% of all endocrine cells of the islet [160, 172]. The complex
functional inter-relationship that exists between the different endocrine cells of the islets is
exemplified in its architecture [166, 173-175]. Indeed, there are differences in the
distribution of endocrine cells within the islets of different species. For instance, as shown
in Figure 6, rodent islets tend to have a core of -cells surrounded by a mantle of - and
other endocrine cells [172, 176], whereas human islets tend to have an intermixed
distribution of - and non -cells. This is particularly notable in islets with a diameter
>60 m where the distribution of endocrine cells resembles that of rodent islets [176].
Irrespective of the mammalian species, islet hormones are secreted to maintain
glucose homeostasis efficiently [91, 93]. Accordingly, insulin is released when blood
glucose levels rise during and after a meal whereas glucagon, which increases blood
glucose levels in the fasting state, is released when blood glucose levels are below the basal
levels i.e., 5.6 mmol/L [91, 93]. Unlike insulin and glucagon, somatostatin and pancreatic
polypeptide do not directly regulate blood glucose levels. Indeed, somatostatin exert a tonic
inhibitory action on the secretion of insulin and glucagon [177] whereas pancreatic
polypeptide controls both exocrine secretion and the secretion of endocrine hormones
[178]. Endocrine cells have the ability to adapt within different metabolic or pathologic
stresses in order to maintain nutrient metabolism homeostasis [166]. It is noteworthy that
the distribution, function and/or growth of these endocrine cells may vary with different
physiological states [172, 179] including aging [94], T2D [173, 180], obesity [181],
pregnancy [182] or age, as -cell mass tends to expand as mice and humans grow older
[160]. Nonetheless, non-obese diabetic (NOD) mice have reduced number of islets with
less number of -cell and a higher number of -cells compared to the control mice [172]

(somatostatin)
Capillary
(pancreatic polypeptide)

(glucagon)
(insulin)

Islet of Langerhans
Human islet

Mouse islet

Diameter 50µm-250µm

Diameter <60µm

Diameter >60µm

Figure 6. The islets of Langerhans in mice and humans. A pancreatic islet (top) is a cluster of
endocrine cells arranged around a portal venous system made of fenestrated capillaries and organized in a glomerular-like fashion. This capillary system is typical of smaller islets and are directly
connected to capillary system of the pancreas. Larger islets usually feature afferent arterioles
forked from intralobular arteries of the pancreas. At least four different types of endocrine cells are
found in a typical islet and each of them produce, store and secrete a single hormone under physiological conditions. These are: glucagon-, insulin, pancreatic polypeptide- and somatostatin-positive

60µm distribute their endocrine cells in a similar fashion as that of mouse islets.
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whereas obese ob/ob mice showed increased islet and -cell number, which was attributed
to increased -cell proliferation [170, 175]. Similarly, studies in human subjects have
suggested that -cells expand in mass, rather than in number in response to obesity whereas
the transition to T2D correlated with decreased -cell mass [172].
Adaptive physiological mechanisms to cope for metabolic demands: The case of -cell
mass dynamics in metabolic diseases
A key aspect of the persistent hyperinsulinemia and insulin resistance typical of
obese individuals with metabolic syndrome is their adaptive and interlinked nature.
Development of insulin resistance in obese individuals appears to be the result of
hypersecretion of insulin from

-cells and/or decreased hepatic clearance i.e., the

elimination of insulin from plasma [120]. However, several other causes of insulin
resistance in obesity may exist. For instance, the ectopic accumulation of triglycerides in
skeletal muscle, liver and pancreas, which contribute to systemic insulin resistance [24].
Irrespective of the causes of insulin resistance, the adaptive plasticity of -cells has gained
major attention for exploring potential causes behind acquired metabolic diseases [32, 70,
183]. Indeed, maintaining a balanced functional -cell mass is particularly crucial to assist
the metabolic demands for insulin as a mean to regulate overall fuel and glucose
homeostasis [184]. To achieve that balance, -cells tend to compensate for the variability
in normal and pathophysiological states. This is inferred through morphological,
quantitative and qualitative changes in -cells usually linked to the formation of new cells (neogenesis), increased cell size/volume (hypertrophy), number due to replication of
pre-existing cells (hyperplasia) and/or changes in the rate of -cell death due to apoptosis
or autophagy (hypo/atrophy) [182, 185, 186]. These changes are summarized in Figure 7.
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In the early stages of insulin resistance, -cell size usually increases leading to
increased insulin secretory capacity needed to compensate for a higher insulin demand [77,
85]. In obese, non-diabetic subjects, -cell mass and insulin synthesis also increase in
parallel to the hyperinsulinemia typical of these cases presumably to help maintain
euglycemia [77, 85, 187]. In fact, -cell mass can increase to an ~50% if insulin resistance
continued [77, 85, 187]. Similarly, the relative -cell volume, calculated as -cells area
divided by exocrine area, increased by almost 50% in obese individuals compared to their
lean counterpart [180]. These increases in mass/volume appears related to increased -cell
replication [85, 188]. However, -cell mass is usually reduced in T2D by ~40-60%
resulting in smaller islets and reduced overall islet and -cell mass, thus potentially
aggravating the already impaired insulin secretory capacity of T2D islets [94, 189]. Studies
have also shown that T2D patients have fewer large islets along with a significant decline
in the percentage of islet -cells [78]. Accordingly, -to- cell interactions have been
shown to decline in T2D [173]. The islet morphology changes observed in
overweight/obese subjects as well as in T2D are not unique of humans. Obese ob/ob mice
show hypertrophy of islet cells in parallel to hyperinsulinemia and adiposity accrual [120].
In animal models of obesity, either polygenic or monogenic, phenotypical and
physiological changes in the islets are indeed noticeable. The study of islet morphometry
has gained considerable interest among researchers studying these changes. For instance,
-cell mas was ~4 times higher in Zucker fatty (ZF) rats, an animal model of monogenic
obesity lacking the leptin receptor [190]. Yet, these rats maintained normoglycemia in the
face of significant hyperinsulinemia and hypertriglyceridemia [190]. However, in high fat
diet mice, an example of polygenic obesity animal model, it has been found that an increase

in body weight was related to a parallel increase in

-cell area and number ( -cell

hyperplasia) [191], probably related to increased -cell replication, as judged by the
increase in the proportion of cells positive for Ki67, a commonly used proliferation marker
[191]. Although the mechanisms behind these changes in -cell mass remain not fully
understood, this research topic is hot [180, 184] as it may hold keys to stop or delay the
current epidemics of acquired metabolic diseases.
In present study, we investigated islet and endocrine cell morphometry changes in
an animal model of overweight/metabolic syndrome developed by our lab: Nkcc1

KO

mice

before and after their development of overweight. The results obtained indicate that
elimination of Nkcc1 from -cell negatively impact -cell volume and mass before the
onset of overweight. Therefore, Nkcc1 may play an important role in the development of
metabolic syndrome.

HYPOTHESIS
Premises: i) The emerging role of abnormal insulin responses in the development
of overweight and obesity, ii) The known effects that Cl– transporters such as Nkcc1 have
on insulin secretion and cell proliferation, and iii) The fact that eliminating Nkcc1 from cells triggers metabolic syndrome, set the stage for the hypothesis that: Loss of -cell Nkcc1
triggers age-dependent -cell loss due to impaired -cell neogenesis thus contributing to
the development overweight and metabolic syndrome.
Two specific Aims are defined to test that global hypothesis:
Aim 1: To determine islet

- and

-cell number, volume and mass of lean and

overweight mice lacking Nkcc1 in -cells.
Aim 2: To determine the number of

-cell clusters in the pancreas of lean and

overweight mice lacking Nkcc1 in -cells.

MATERIALS AND METHODS
Mice
All experiments were conducted on fixed pancreas tissues obtained from perfused
male mice aged 10 and 30 weeks. All procedures involving mice were done in accordance
with the guidelines recommended by the Institutional Animal Care and Use Committee
(IACUC) of the Boonshoft School of Medicine, Wright State University. Mice were
weaned and housed in groups in polycarbonate cages and were provided ad libitum access
to water and a rodent chow diet (Teklad 22/5 no. 8640, 3kcal/g). Mice were housed in
12:12 hour light and dark cycle at ambient temperature and humidity. All mice were on the
C57BL/6J genetic background and crossed for <10 generations. Mice harboring loxP sites
flanking exon 8-10 of the Nkcc1 gene (Nkcc1lox/lox) were kindly provided by Dr. Christian
A. Hübner (Jena University, Germany). Mice expressing Cre-recombinase in insulin
positive -cells (Ins1Cre) were from Jackson Labs (Stock #026801) [192] and used to
generate mice lacking Nkcc1 in -cells. As control, we used Nkcc1lox/lox mice instead of
Ins1Cre because the presence of "floxed" alleles was not associated with changes in glucose
homeostasis as determined by basal/fed blood glucose, plasma insulin, glucose and insulin
tolerances, consistent with previous reports [192-194].
Animal perfusion and tissue processing
Mice were deeply anesthetized with Euthasol® (2µl/gBW) and transcardially
perfused as described previously [130]. Briefly, a 30G needle, (tubed with 1xPBS +
Heparin with standard flow rate of 1.7ml/min) was inserted into the apex of the left
ventricle of the mouse’s heart. The right atrium was next punctured using standard scissors

to drain the blood out of circulation. Upon complete washout of the blood, mouse was then
perfused with 4% paraformaldehyde (PFA) solution. Pancreas was then collected and
incubated overnight with 4% PFA at 4°C overnight. Next day, tissues were kept in a 30%
sucrose solution at 4°C until processing at AML laboratories (St. Augustine, FL).
Histochemistry
Weighed pancreas tissues from mice were post-fixed, sectioned every 100 m,
stained with hematoxylin-eosin (H&E, Sigma-Aldrich #HHS16) and mounted (Permount
SP15-100, Fisher Sci., Waltham MA) to capture histological images and assess tissue
morphology

and

overall

health.
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were deparaffinized with xylene twice for three minutes each. Sections were then
rehydrated by sequentially submerging them in 70%, 95% and 100% ethanol and distilled
water for 3min each. Slides were then stained by soaking in hematoxylin solution for 4min
and then kept under running tap water for 20min to change the color from red to blue.
Following that, slides were washed 3 times with distilled water and 70% ethanol for 3min
each. After staining with hematoxylin, tissue slides were incubated for 4min with eosin
prepared by mixing Eosin Y (#SE23-500D, Fisher Chemical, MA), 1% Phloxine B
(#19350 Certified Generon, Electron Microscopy Sciences, PA), 95% ethanol and 4ml
glacial acetic acid (VWR International, PA). To remove excess staining, slides were
washed 3 and 5 times in 95% and 100% ethanol, respectively. Slides’ washing was
finalized by submerging them in xylene for 30s to clarify tissues appropriately. Tissue
sections were mounted by placing immunofluorescence microscopy-grade glass coverslips
(#12545F, Fisher Scientific, Waltham, PA) on top and sealed by using CoverGrip
coverslips sealant (Biotium Inc., San Francisco, CA) and digitally imaged (see below).

Immunofluorescence microscopy
Immunofluorescence staining was performed as described elsewhere [195]. Briefly,
tissue sections were deparaffinized in xylene for 5min and rehydrated to remove excess
xylene. Tissue sections were then serially soaked for 5min in ethanol 100% (2 times), 95%
(1 time) and 1 time for 2 min in 70%, 50%, 30% and left in 95% ethanol for 5 additional
min. After rehydration, tissue slides were washed with distilled water and phosphate buffer
saline (PBS, Fisher Scientific, Walthman, PA) for 5 and 10min respectively. Antigens were
then retrieved by placing the slides in 10mM sodium citrate buffer at 95°C water bath for
30min. Following that, slides were washed 2 times for 5min each in PBS. Tissue sections
were then incubated at 4°C for 15min in 4% PFA (#15710 Electron Microscopy Sciences,
Hatfield, PA) and 0.3% Triton (Acros Organics, Geel Antwerp, Belgium) in PBS to allow
permeabilization of tissue sections and facilitate the uptake of antibodies. Next, blocking
of non-specific binding sites in tissues was performed by incubating the slides in blocking
buffer consisting of goat or donkey serum diluted in PBS (3%). Tissues were then
incubated for 1h at 4°C and overnight in the presence of primary antibodies diluted in
blocking buffer. The - and -cells of the islets in pancreas sections were immunolabeled
with antibodies against glucagon and insulin, respectively, purchased from Abcam and Cell
Marque. Those antibodies were coupled to fluorophore-conjugated secondary antibodies
Cy3-IgG and Alexa Fluor 488-IgG, respectively, purchased from Jackson Immune
research. Next day slides were washed 3 times in PBS for 5min each and incubated with
appropriate labeled secondary antibodies for 1h at room temperature. Slides were then
washed 6 times with PBS for 5min each. Excess PBS on slides was removed by using
Kimtech wipes (Z188956-1 Sigma Chem. Co. Saint Louis, MO) and tissue sections

covered with glass coverslips after placing 20 l of mounting media (Vectashiled H-100010, Vector Laboratories, San Francisco, CA) for digital imaging.
Digital imaging
Bright field and immunofluorescence microscopy images were taken by using an
Olympus DP73 digital color camera attached to Olympus BX51 fluorescence microscope.
The camera converts analog electrical signals to digital ones (ADC) at a resolution of
14bits. It has a maximal resolution of 4800 (w)

3600 (h) pixels (px) and detects a

minimum px size of 4.4 4.4 m (19.36 m2). The minimal/maximal exposure time of the
camera is 23 s/60s. The digitized data transfer via dedicated hardware controller to a
personal computer to be displayed in real time on the screen. Digital images are optimized,
taken and stored by using the software interface Olympus cellSens® Standard v2.3
(Olympus, Center Valley, PA). All digital images were captured under the following
conditions: 40 and 20 magnification, 50-200ms exposure, ISO 100, resolution power
4800 3600px shift for snapshots and 800 600 (binning 2 2) for live captures.
Images were stored using the multilayered Photoshop® document format (.psd) at
17.3 million px2 to maintain the resolution of the images. Over 5,000 images were
individually catalogued. Every digital image captured contained at least a single islet or
cluster of endocrine cells and included ruler scales corresponding to the magnification
used. Images were named according to the following criteria: mouse genotype [either 1F
(Nkcc1flox/flox) or iC1F (Ins1Cre:Nkcc1flox/flox)], identification (ID), age (10w-30w), slide
number (s1-s10) and section on slides (from left to right: 1st, 2nd and 3rd). Whole tissue
sections were imaged by stitching individual images taken at 4 magnification at ~9001000ms exposure time. These stitched images were computed and assembled by the

Multiple Image Alignment (MIA) by using either instant MIA or Manual MIA. To fix px
resolution in instant MIA, the "always overwrite" feature was used. In case of manual MIA,
the stage was manually directed by clicking on the corresponding arrows.
In silico morphometry parameters
Captured digital images were converted to Tag Image File format (.tiff) or Portable
Network Graphic (.png) formats to reduce file size without affecting pixels density by
using Adobe Photoshop CS5® (Adobe Corp., San Jose, CA). Unmodified converted images
were processed by using the open source software ImageJ/Fiji [196], publicly available at
imagej.net/software/fiji/. We used version 2.3.0/1.53f, built d544a3f4881 for MacOS
(v10.13.6). The following morphometry parameters were computed:
1) Endocrine cell areas ( m2) consisting in the net calibrated tissue area corresponding
to all islet insulin-positive -cells, glucagon-positive -cells or both, being the latter
considered here as the total islet area. The areas corresponding to somatostatin and
ghrelin-positive - and -cells, respectively, were assumed to be <3% of the total
islet [197] and therefore, they were not determined in these studies.
2) Relative -cell, -cell and islet density were calculated by dividing individual
endocrine cell areas per tissue section area (%, m2).
3) Endocrine cell number i.e., the net sum of nucleated insulin- and/or glucagonpositive cells found within an islet (counts/islet).
4) Endocrine cell volume (pL) calculated assuming that - and -cells have spherical
shape (VEC = 4/3 r3). The mean radio r of - and -cells was computed from
individual cell surface area computed by dividing the mean number of nucleated
endocrine cells per specific endocrine area (r2 = area/ ).

5) Endocrine cell mass (g) was calculated by multiplying endocrine cell area (mm2)
per tissue section area (mm2)

mean pancreas weight (g)].

6) Isolated endocrine cell clusters containing 4 -cells or single -cells found within
ductal epithelial cells were not considered islets but were counted as proto-islets
and expressed per unit of tissue section area (counts/mm2). Proto-islets were
considered potential neogenic islets [198, 199].
Statistical analysis
Results are presented as mean values ± SEM, with the number of individual points
(n) indicated. Statistical significance was considered when p<0.05. To determine
differences between groups, one-way or two-way analyses of variance (ANOVA) were
used, as appropriate, followed by the Tukey-Kramer post-hoc test. Statistical analyses were
conducted by using GraphPad Prism® v5 (GraphPad Software Inc., San Diego, CA, USA).
Normal distribution and homogeneity of data variance were tested using Shapiro-Wilk and
F-tests, respectively.

RESULTS
The results presented here are divided into two main sections. The first one relates
to the calibration and quality control of hardware and software used for image collection,
tissue morphometry and quantification of islets dimensions. The second one, relates to data
analysis/interpretation.
Calibration and quality control of ImageJ/Fiji
Software quality control
Unmodified digital images with scale bars incorporated in them were converted to
the tiff format and opened by dragging them onto ImageJ/Fiji software for initial scale
verification and quality control. To verify if the electronically embedded scales correspond
to their defined length in m, they were validated on digital images of a ruler of known
length digitally pictured at 100 , 200 and 400 magnification. As shown in Figures 8A,
8C and 8E, each scale bar faithfully represents the m of the ruler indicating that the
microscope is properly calibrated. Next, we determined the equivalence between m and
linear px, the only unit of measurement of ImageJ/Fiji because the software assumes by
default that every single px equals 1/96 inches i.e., 1px = 26.5mm (1px2 = 702.25mm2 =
7.0225 108 m2), which does not reflect the real size/area of any digital image taken using
a microscope with calibrated magnification lenses. Therefore, we determined the
relationship between software px and m in the digital pictures shown in Figures 8A, 8C
and 8E. To measure the number of linear px corresponding to the ruler, we used the
Straight-line tool of ImageJ/Fiji. In doing so, horizontal lines of exact length as that of the
ruler were drawn on each image. As shown in Figures 8B, 8D and 8F, ImageJ/Fiji
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x100 magnification (1159px × 484px)
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D

x200 magnification (1398px × 930px)

E

F

x400 magnification (958px × 173px)
Figure 8. ImageJ/Fiji quality control. Shown are digital pictures of calibrated rulers placed under
the microscope at magnifications corresponding to 100× (A), 200× (C) and 400× (E). Red arrows on
A, C and E indicate yellow horizontal lines manually drawn by using the Straight line tool of
ImageJ/Fiji to match the exact length of of the indicated ruler divisions i.e., 300µm, 50µm and 20µm
in A, C and E, respectively. Red circles on A, C and E indicate the length in µm determined by the
microscope software, with matches that indicated by the rulers at each magnification. Shown in B,
D and F are the ImageJ/Fiji box dialogs invoked by the Set Scale command to show the number of
linear px (Distance in pixels) determined by ImageJ/Fiji and corresponding to the length of yellow
lines in A, C and E, respectively. Red arrows on B, D and F indicate 300µm, 50µm and 20µm i.e.,
the correct number of px (manually entered in Known distance) matching microscope scales and
rulers in A, C and E, respectively.
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measures different lengths in px for the same ruler at different magnifications, as expected.
Since the length of the ruler is known, scales are calibrated by correcting the distance in px
measured by the software for the real ones represented in the ruler i.e., 1.33px/ m,
4.54px/ m and 4.65px/ m for images taken at 100 , 200

and 400 , respectively.

Therefore, each px measured can be transformed into calibrated area in m2. That is, for
calibrated scales of 1.33px/ m, 4.54px/ m and 4.65px/ m, each px measured by the
software corresponds to 0.57 m2, 0.049 m2 and 0.045 m2, respectively.
Software scale setup
After quality control/calibration and before starting morphometry measurements,
ImageJ/Fiji was forced to measure calibrated px in digital images of 17.28Mpx2 taken by
the microscope. To that end, we first convert measured px to m/ m2 by setting scale
parameters, as indicated in Figure 9 and following these steps:
1. By using the Straight-line tool in ImageJ/Fiji, a horizontal line was drawn atop
scale bars included in all microscopy images, as exemplified in Figure 9A.
2. Then, from the Analyze menu, Set-scale was chosen to evoke the dialog box shown
in Figure 9B and similar to those depicted in Figures 8A, 8C and 8E.
3. Since the length of the scale bar in digital pictures is depicted in uncalibrated px by
ImageJ/Fiji, we corrected them by filling the Known distance box with the
calibrated measure while keeping the Pixel aspect ratio to 1, because each px
correspond to a given m.
4. To force ImageJ/Fiji to perform identical calibrated measurements to all digital
images acquired at the same magnification, the Global box was checked.

A

x200 magnification

B

Figure 9. ImageJ/Fiji scale setup. A. Representative digital picture taken at 200× magnification of
a mouse pancreas section containing two islets immunolabeled against insulin (red). The red arrow
in A indicates a horizontal yellow line manually drawn by using the Straight line tool of ImageJ/Fiji to
match the exact length of the calibrated scale of 50µm embedded by the microscope’s software
(see magnification underneath A). B. Shown is the ImageJ/Fiji box dialog invoked by the Set Scale
command to show the number of linear px (Distance in pixels) determined by ImageJ/Fiji and
corresponding to the length of the yellow line in A. The red arrow on B indicate 50µm i.e., the correct
number of px (manually entered in Known distance) to match the calibrated scale in A.
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Measuring -cells and -cells area
After setting up calibrated parameters in ImageJ/Fiji, we next manually measured cell and -cell islet areas, as shown in Figure 10 and by following the steps indicated
below:
1. By using the Free hand tool in ImageJ/Fiji, a continuous line was drawn to encircle
islet -cell or -cell areas
2. Then, from the Analyze menu, the option Measure was chosen to determine the
number of m2 corresponding to islet -cell or -cell areas
3. This procedure was repeated for more than 700 pancreatic islets found in tissue
sections immunolabeled against insulin ( -cells) and glucagon ( -cells).
Determining the number of - and -cells in islets
Following a similar strategy to that performed to determine / -cell area, we manually
counted cell nuclei corresponding islet -cells and -cells, as shown in Figure 11 and by
following the steps indicated below:
1. By using the Multi-point tool in ImageJ/Fiji, each -cell and -cell nuclei was
labeled with a marker of a unique color
2. Then, from the Analyze menu, the option Measure was chosen to determine the
total counts of colored markers corresponding to -cell or -cell nuclei
3. This procedure was repeated for more than 1400 individual islet cells found in
tissue sections immunolabeled against insulin ( -cells) and glucagon ( -cells).
Estimation of tissue section area
To determine the total area of whole tissue sections, a series of steps were followed,

D

C

E

F

Figure 10.
Representative digital pictures taken at
200× magnification of a mouse islet immunolabeled against glucagon (A, green) and insulin (B,
C.
D.

7

2
2

2

40

B

Figure 11.
Representative digital picture of
a mouse islet immunolabeled against glucagon (A, green) and insulin (B, red). Each nucleus
using the Cell Counter plugin of ImageJ/Fiji. B.

as summarized in Figure 12. First, the scale was set to determine the px/ m2 equivalence
of 40 images of 478.9Mpx2 by following similar steps as those indicated previously.
Then, from ImageJ/Fiji menu, the path Image>Adjust>Color threshold was followed to
adjust the overall brightness of the images and reach the threshold whereby only the whole
tissue was filled with a red color. After identifying the whole tissue area, the Wand tracing
tool was chosen, which allowed for the selection of the whole tissue area while the key
Shift was held pressed. To measure selected tissue areas, we used the Measure function
from the Analyze menu of the software. The calibrated area in m2 corresponding to the
whole section was converted into mm2 by dividing the area measured by 10–6. These steps
were repeated for more than 50 tissue sections.
Data analysis
Reduced -cell counts in 10w old Nkcc1

KO

mice

Nkcc1 plays a pivotal role in the regulation of cell homeostasis by participating in
cell proliferation [145]. To determine whether loss of Nkcc1 from -cells would alter islet
cell counts, we immunolabeled -cells against insulin. As shown in Figure 13A, the total
-cell number determined in the pancreas of 10w old Nkcc1

KO

mice was significantly

decreased relative to age-matched wildtype (WT). This decrease was apparently
compensated later in life, since -cell number was similar in 30w old Nkcc1
mice. Therefore, this data demonstrate that younger Nkcc1

ko

KO

and WT

mice have reduced -cell

number, which normalizes later in life.
-Cell hypoplasia in 10w and 30w old Nkcc1

KO

mice

Since the number of -cell decreased at 10w, we next tested the hypothesis that

A

B

C

D

Figure 12. Measuring whole tissue section area. A. Representative digital picture of a mouse
pancreas section (5µm thickness) taken at 40×. Arrows indicate islets. B-C. Shown are snapshot
images of A after adjusting the color threshold (B) to select total tissue section areas in the image
(C) by using the ImageJ/Fiji Wand tracing tool. D. Box dialog invoked by activation of the Threshold
function of ImageJ/Fiji. After selecting tissue areas, the Measure function of ImageJ/Fiji was used to
estimate area in calibrated µm2.
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Figure 13. Pancreas weight, total islet area, islet density and frequency in Nkcc1
mice. A.
Net wet pancreas weight recorded after perfusion of mice of the indicated genotypes and ages
(n=6-8). B-C. Islet area (µm2) computed by using pancreas digital images either H&E-stained (B)
or immunolabeled against insulin and glucagon (B) from 10w and 30w old Nkcc1
and control
mice. Each point in B represents the area of a single islet (n=3 per genotype and age). Each point
in C represents the mean area of all islets found in a single tissue section (n=21) from mice (n=3
per genotype and age). D. Relative frequency distribution of islets area (bins of 2500µm2)
computed from data in C.
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Nkcc1

KO

mice have reduced -cell volume, based on the fact that Nkcc1 participates in

cell volume regulation and a reduction in [Cl–]i causes cell shrinkage [136-138]. The results
shown in Figure 14A demonstrate that -cells volume of 10w old Nkcc1

KO

mice is

significantly reduced relative to age-matched control. In fact, this reduction remained in
older Nkcc1

KO

mice. Therefore, these results indicate that elimination of Nkcc1 from -

cells results in reduced cell volume, which cannot be reversed with aging.
Reduced -cell mass in 10w and 30w old Nkcc1

KO

mice

Reduced -cell number and volume predicts reduced -cell mass. Therefore, to
ascertain that, -cell mass was determined from pancreas sections of 10w and 30w old
Nkcc1

KO

and control mice as indicated in the Materials section. The results shown in

Figure 14D demonstrate significant reduction in -cells mass of 10w old Nkcc1

KO

mice

but that found in 30w of age did not attain significance. Therefore, reduced -cell number
and volume results in overall reduced -cells mass in 10w old Nkcc1
Nkcc1

KO

KO

mice whereas older

mice partially compensate that reduction.

Decreased number of -cell clusters (proto-islets) in Nkcc1

KO

mice

-cell clusters are considered proto-islets i.e., precursors of islets and possible
markers of -cells neogenesis [199]. These clusters, defined as single (1-4) scattered
insulin-positive cells, are found randomly distributed in pancreatic tissues. Therefore, to
determine if the reduced

-cell number of Nkcc1

KO

mice is associated to reduced

neogenesis, we counted the number of -cells clusters on insulin-labeled pancreas tissue
sections from 10w and 30w old Nkcc1

KO

mice. The results shown in Figure 15A

demonstrate significant decreased -cells clusters in 10w and 30w old Nkcc1

KO

mice
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relative to age-matched control, thus suggesting reduced -cell neogenesis.
Normal -cell fluorescence intensity and islet insulin content in Nkcc1

KO

mice

We have previously shown that islets from mice lacking Nkcc1 have deficient
secretory responses [Manuscript under review]. Therefore, to determine if decreased cells number, size and mass is accompanied by changes in -cell function, we next
measured -cell fluorescence intensity from tissue sections of 10w and 30w old Nkcc1

KO

mice immunolabeled against insulin and islet insulin content from purified islets of 20w
old Nkcc1

KO

mice. As shown in Figure 16B and 16A insulin fluorescence intensity and

insulin content in 10w and 30w old Nkcc1

KO

mice was similar to that of control. Therefore,

together these results suggest that there is no difference in -cell secretory capacity of
Nkcc1

KO

mice.

Conserved -cell count, volume, area and mass in 10w and 30w old Nkcc1

KO

mice

To determine the specificity of morphometric anomalies found in
Nkcc1

KO

-cells of

mice, we extended our analysis to glucagon-secreting -cells. To that end, we

determined -cell count, volume, area and mass in 10w and 30w old Nkcc1

KO

mice. The

data shown in Figure 17 demonstrate no major changes in -cell morphometry parameters
including -cell number (A, counts per islet), volume (B, pL), area (C, m2; and D, % of
pancreas section) and -cell mass (E, mg) in 10w and 30w old Nkcc1

KO

and control.

Therefore, these data suggest normal islet -cell morphometry implying Nkcc1

KO

mice

have reduced islet size due to hypoplastic and hypotrophic -cells.
Increased -to- -cell ratio in Nkcc1

KO

mice

The results presented so far indicate -cell specific morphometry anomalies in islets
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Figure 17. Islet insulin content and insulin-immunofluorescence intensity. A. Shown is the
insulin content expressed in nanograms (ng) per islet equivalent (iEq). Data represent the mean ±
n=3) of the indicated genotypes and
ages. B-C.
control and Nkcc1
mice. Bars indicate 20µm.

50

of mice lacking Nkcc1 in those cells. Therefore, we determined the -to- -cell ratio in 10w
and 30w old Nkcc1
ratio in Nkcc1

KO

KO

mice. The data shown in Figure 17F confirms increased -to- -cell

mice at both ages when compared to their age-matched control, although

such increase was not significant at 30w of age.
Decreased islet size in 10w and 30w old Nkcc1

KO

mice

To verify the previous assumption that reduced in -cell mass, volume and mass is
directly reflected in hypoplastic islets, we next determined the mean islet area, islet size
distribution and the islet-to-pancreas area ratio of 10w and 30w Nkcc1

KO

mice. As

predicted, the results shown in Figure 18B demonstrate significant decreased islet size in
Nkcc1

KO

mice compared to age-matched control. Further, the islet size distribution data

shown in Figure 18D demonstrate that mice lacking Nkcc1 in -cell have increased number
of smaller isles than control mice whereas the data in Figure 18C demonstrates reduced
islet density in Nkcc1

KO

mice. Therefore, when taken together these results demonstrate

that elimination of Nkcc1 in -cells results in increased number of small islets and reduced
mean islet size.
In summary, our results suggest that show that decreased
participates in the development of the metabolic phenotype of Nkcc1

-cell neogenesis
KO

mice. In this

situation, -cell hypotrophy is observed, characterized by reduced -cell volume and mass.
-cell hypotrophy causes a general islet hypoplasia. This hypoplasia was observed in lean
Nkcc1

KO

mice at 10 weeks of age, which implies that the changes in islet morphometric

parameters precede the onset of the overweight. This altogether suggest a
pathophysiological link between -cell Nkcc1, impaired -cell neogenesis and metabolic
syndrome.
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DISCUSSION
The relationship that exist between disturbed insulin secretion and the
pathophysiology of chronic metabolic diseases such as obesity, metabolic syndrome and
diabetes is highly complex [91]. Since 40-70% of obesity cases can be attributed to
hereditary components [200] animal models have been extensively used to better
understand the physiological mechanisms controlling body weight gain [31, 32]. By using
the Cre/Lox system [201], we have recently generated and metabolically characterized a
new mouse model lacking Nkcc1 specifically in insulin-secreting -cell. These Nkcc1

KO

mice developed overweight, hyperlipidemia, hyperglycemia, glucose intolerance, insulin
resistance and non-alcoholic steatohepatitis, a metabolic phenotype attributed to deficient
islet function [Manuscript under review].
It is known that Nkcc1 is involved in -cell electrical activity and insulin secretion
[20]. Here, we presented evidence indicating that this functional reduction in islet secretion
is not related to evident changes in insulin content (Fig. 16). Insulin secretion is usually
estimated as the ratio between insulin released into the media and the total content of the
hormone in cells. Insulin content was measured in 22w old Nkcc1

KO

and control islets of

equivalent diameter (~50 m). Therefore, the reduction of insulin secretory responses in
Nkcc1

KO

islets with normal insulin content is related to a specific reduction in the number

of hypotrophic and hypofunctional -cells. In Nkcc1

KO

islets, -cell morphometry appears

normal (Fig. 17), suggesting that the morphometric changes are specific to -cells.
It is noteworthy that islets of T2D patients usually have increased -to- -cell ratio
[202, 203], which is usually attributed to higher -cell mass [203]. On the contrary, our
results suggest no major changes in the overall -cell mass of Nkcc1

KO

mice (Fig. 18E).

However, the -to- -cell ratio of 10w old Nkcc1
18F) due to the fact that islets of Nkcc1

KO

KO

mice was significantly increased (Fig.

mice have a more pronounced decrease in the

number of -cells (Fig. 14A) than the increase in

-cells (Fig. 18A). Similarly, the

apparently normal -to- -cell ratio of 30w old Nkcc1

KO

mice is in fact the result of a

similar increase in the number of - and -cells. Therefore, these data suggest that the
overall reduced secretory function of Nkcc1

KO

islets mainly relates to reduced -cell

function and number rather than major functional/morphological alterations in -cells. This
is somewhat expected due to the notion that Nkcc1 has not been found in -cells [153] and
that Nkcc1 is involved in the regulation of cell proliferation [136-138]. In fact, Nkcc1 seems
necessary for the proliferation of glioma cells [137]. In addition, Nkcc1 overexpression is
related to invasion and proliferation of esophageal squamous cells [141], glial cells [142],
as well as prostatic cells [143]. Further, several studies have demonstrated a link between
Nkcc1 function and cellular proliferation. In fact, the link between absence of Nkcc1 in cells and reduced

-cell number is not surprising: Nkcc1 participates in cell cycle

progression and proliferation of mouse fibroblasts [147], chondrocytes [150], vascular
endothelial cells [144], human fibroblasts [145], lymphocytes [204], corneal epithelial cells
[148] and abnormal cells such as PC3 [143] and primary gastric cancer cells [149].
Actually, inhibition of Nkcc1 reduced proliferation neuronal progenitors [205, 206] i.e.,
cells with the capacity to produce neuronal and glial cells [207]. Further, inhibition of
Nkcc1 reduced GABA-mediated electrical activity of these progenitor cells [206], whereas
activation of ionotropic GABA receptors, which are Cl– channels, increased mouse and
human -cell mass [139, 140]. Our results demonstrating that elimination of Nkcc1 from
-cells significantly decreased the number of -cell clusters (proto-islets) in 10w and 30w

old Nkcc1

KO

mice (Fig. 16) support the role of Nkcc1 as a regulator of cell proliferation.

Indeed, several studies have proposed the presence of proto islets as markers of -cell
proliferation and as precursors of fully functional islets [199, 208-211].
Cell proliferation and cell volume regulation are interlinked cellular processes.
Inhibition of Nkcc1 decreased glioma cell growth [137, 212] by facilitating their migration
through dynamic changes in their volume [138, 212]. Cell swelling of -cells appears to be
a vital component of the secretory response [124, 213, 214]. For instance, glucose increases
-cell volume [215-218] and inhibition or elimination of Cl– channels involved in -cell
swelling, such as VRAC, impairs insulin secretion [124, 213, 214]. Notably, the role of
Nkcc1 in cell volume regulation is very well known [152, 219] and a wealth of information
suggest that inhibition of Nkcc1 in -cells reduces cell volume, electrical activity and
insulin secretion [105, 153-156, 213, 215, 220-222]. Further, we have demonstrated that
-cells lacking Nkcc1 are shrunken [157] and our results shown in Fig. 15 confirm the
notion that -cell volume is regulated, at least in part, by the functional presence of Nkcc1.
In addition, -cell volume remained normal in 10w and 30w old Nkcc1

KO

islets, consistent

with the fact that Nkcc1 is not found in -cells [153]. Therefore, together these results
suggest that reduced cell volume and/or its deficient regulation in -cells lacking Nkcc1
contribute to the deficient response to glucose observed in Nkcc1

KO

islets in vitro

[Manuscript under review].
The reduced number of -cells (Fig. 14) and their reduced cellular volume (Fig. 15)
help explain the fact that, in average, Nkcc1

KO

islets were smaller than control ones (Fig.

13). Additionally, in comparison to normal mice, the relative number of smaller islets was
increased in 10w old Nkcc1

KO

mice (Fig. 13D) but not significantly in older ones (Fig.

13D) whereas -cell mass remained reduced in these mice (Fig. 15D). Therefore, these data
suggest that Nkcc1

KO

mice have reduced total number of pancreatic islets, a loss that

deepens in older mice. This interpretation is further supported by the fact that the number
of

-cell clusters found in the pancreas of 10w and 30w old Nkcc1

KO

mice were

significantly reduced when compared to control mice (Fig. 16). At this point, one could
speculate that the overall reduction in -cell mass may play a causative role or contribute
to the development of the metabolic phenotype of Nkcc1
significantly reduced in 10w old Nkcc1

KO

KO

mice. Indeed, -cell mass was

mice, which are lean, thus implying that reduced

-cell mass and -cell function may play a key role in the development of overweight.
Further, 30w old Nkcc1

KO

mice developed overweight and exhibited components of the

metabolic syndrome, which are frequently attributed in the literature to disrupted insulin
release, in turn triggered by -cell dysfunction and/or impaired -cell proliferation [32, 70,
183]. This also implies that -cell dysfunction and/or impaired -cell proliferation is
present before the onset of overweight and that the latter precedes hyperglycemia, glucose
intolerance and the metabolic syndrome.
Abnormal insulin responses to food were linked to the pathogenesis of obesity
[223]. Interestingly, overweight/obesity progression are attenuated by reducing insulin
responses [224-228] and pharmacological inhibition of insulin release decrease food intake
in rats [229] and in humans [230], thus overall suggesting that altered -cell function/mass
may play an important role in the modulation of body weight gain and the development of
metabolic syndrome. In addition, prandial insulin responses reduce meal size i.e., increase
satiation [231] and portal insulin has a role in the satiation control of food intake [232]. As
insulin increases satiation and the pancreatic

-cell is the main producer of insulin,

disruption of -cell function could negatively impact the satiation control of food intake.
Therefore, these data and our results support the hypothesis that islet-specific deficiencies
in insulin responses to food alter short/long term control of feeding behavior driving
overweight and metabolic syndrome in Nkcc1

KO

mice. However, it remains to be

demonstrated whether altered feeding behavior predicts the development of overweight
and metabolic syndrome.
It is usually accepted that normoglycemia during physiological and pathological
changes in fuel demand is maintained by an adequate number of functional -cells in
humans and animal models [184, 233, 234]. However, some controversy exists as to
whether the physiological compensatory increase in -cell function that occurs during
pregnancy or obesity is solely attributed to -cell proliferation [233, 235] and increased
islet size [236]. Our results indicate that mice lacking Nkcc1 in -cells appear deficient in
such capacity because -cell mass remained reduced (Fig. 15D) in 30w old overweight
mice with a metabolic phenotype. These data imply that -cells lacking Nkcc1 may still
play a functional compensatory role in 10w old Nkcc1
normoglycemic, but not at older ages, when Nkcc1

KO

KO

mice, that is, when mice are

mice became hyperglycemic, insulin

resistant and glucose intolerant [Manuscript under review]. In addition, the reduced number
of -cell clusters and -cell mass demonstrated in 30w old Nkcc1

KO

mice suggest that

functional -cell compensation is hampered in the absence of a parallel -cell mass in
response to overweight.
In conclusion, our results showed that Nkcc1 plays an important role in -cell
neogenesis. Since Nkcc1

KO

mice develop the phenotypical characters of metabolic

syndrome, this suggests that Nkcc1 plays an important role in the development of

overweight and its progression to metabolic syndrome. Moreover, our data provides
evidence suggesting that Nkcc1-deficient -cells are unable to compensate, at least in
number and mass, for the increased metabolic demand of overweight Nkcc1

KO

mice.
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